---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-000517"
form_type: "8-K"
ticker: "PAVM"
cik: "0001624326"
company_name: "PAVmed Inc."
filed_at: "2025-03-25T23:59:59+00:00"
generated_at: "2026-05-24T05:48:19.728876+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# PAVmed reports Q4 net income $1.3M; Lucid record tests, Veris financing, debt restructured

## Summary
- GAAP net income $1.3M ($0.12 diluted EPS); non-GAAP adjusted loss $0.7M ($0.06) per share.
- Lucid processed 4,042 EsoGuard tests in Q4 (+84% YoY); secured first insurance coverage from Highmark Blue Cross Blue Shield.
- Veris closed ~$2.4M private placement at $35M pre-money valuation to advance implantable monitor toward FDA clearance.
- PAVmed cash $1.2M at Dec 31; pro forma $3.6M including Q1 2025 private placement.
- Deconsolidation of Lucid and convertible debt restructuring added ~$25M to equity, regaining Nasdaq minimum equity compliance.

## SEC filing metadata
- accession: 0001641172-25-000517
- form_type: 8-K
- ticker: PAVM
- cik: 0001624326
- company_name: PAVmed Inc.
- filed_at: 2025-03-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1624326/000164117225000517/0001641172-25-000517-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1624326/000164117225000517/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-000517
- JSON: https://secwatch.observer/filing/0001641172-25-000517.json
- Plain text: https://secwatch.observer/filing/0001641172-25-000517.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.